Sign In
Buy IVA
$4.04
-0.0500 (-1.22%)
At Close: Jun 03, 2026
Daix (France), Long Island City (New York, United States), October 21, 2024 - Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical comp
Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical co
Inventiva announces Filing of 2024 Half-Year Report – Conditions for Accessing or Consulting the Report
02:35am, Monday, 14'th Oct 2024
Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical co
Inventiva announces financing of up to €348 million to advance the NATiV3 Phase 3 MASH study
02:30am, Monday, 14'th Oct 2024
Daix (France), Long Island City (New York, United States), October 14, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical co
Inventiva (IVA) Loses -17.66% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Tuesday, 01'st Oct 2024
Inventiva (IVA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates
Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results
04:00pm, Wednesday, 25'th Sep 2024
Daix (France), Long Island City (New York, United States), September 25, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on
Inventiva Reports Preliminary 2024 First-Half Financial Information¹
04:00pm, Wednesday, 31'st Jul 2024
Daix (France), Long Island City (New York, United States), July 31, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the d
Inventiva secures a new patent in Japan, expanding the IP protection of its lead product candidate lanifibranor
04:00pm, Thursday, 25'th Jul 2024
Daix (France), Long Island City (New York, United States), July 25, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical compa
Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuvreux
11:30am, Friday, 19'th Jul 2024
Daix (France), Long Island City (New York, United States), July 19, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical compa
Inventiva announces a €20.1 million issuance of royalty certificates
02:30am, Thursday, 18'th Jul 2024
Daix (France), Long Island City (New York, United States), July 18, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical compa
Inventiva: Solid MASH Program With Potential For Strategic Partnership Advancement
02:36pm, Monday, 08'th Jul 2024
Inventiva S.A. top-line results from phase 3 NATiV3 study, using lanifibranor for the treatment of patients with MASH, expected by 2nd half of 2026. The 4th pass of the safety review of the DMC was co
Daix (France), Long Island City (New York, United States), July 5, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical compa
Results of the votes of the Combined Shareholders' General Meeting of June 20, 2024
04:00pm, Friday, 21'st Jun 2024
Daix (France), Long Island City (New York, United States), on June 21, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on th
Down -27.95% in 4 Weeks, Here's Why You Should You Buy the Dip in Inventiva (IVA)
10:35am, Tuesday, 18'th Jun 2024
Inventiva (IVA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates
Combined General Meeting of June 20, 2024 - Availability of the preparatory documents
02:30am, Thursday, 30'th May 2024
Daix (France), Long Island City (New York, United States), May 30, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral sm
